The stock was pulled down by the undertow of the broader market sell-off.
News & Analysis: Editas Medicine
EDIT earnings call for the period ending .
After a huge run-up in valuation, investors are a little spooked.
Turnover at the top of a company can be troubling. But it can sometimes be a good thing.
In a field that's becoming more crowded, what will set Editas apart?
Investors reacted negatively to a major deal announced by Editas' former partner with another gene-editing biotech.
Could this maverick biotech discover the cure for several debilitating rare diseases?
One of the biotech's top executives is leaving.
The gene-editing stocks are being pulled down by a broader biotech sell-off.
Here are some best guesses about the biotech stock's huge jump.